Loading
INBRX-106 is an experimental monoclonal antibody from Inhibrx Biosciences in phase 3 trials for head and neck squamous cell carcinoma, with its target not yet stated publicly.
INBRX-106 is a monoclonal antibody developed by Inhibrx Biosciences. The sponsor describes its target as OX40, which OnCo does not yet have a target page for. The sponsor states: A hexavalent OX40 agonist antibody designed to promote hyperclustering of OX40, giving more potent activation of the OX40 costimulatory pathway than traditional Fc-crosslinking-dependent bivalent OX40 antibodies. ClinicalTrials.gov describes the intervention as: INBRX-106 by intravenous (IV) infusion, given every 3 weeks (QW3). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06295731 (INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC), in head and neck squamous cell carcinoma. The largest, NCT06295731, plans to enrol 410 participants with primary completion expected 2029-05. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
A hexavalent OX40 agonist antibody designed to promote hyperclustering of OX40, giving more potent activation of the OX40 costimulatory pathway than traditional Fc-crosslinking-dependent bivalent OX40 antibodies.
1.INBRX-106 binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"INBRX-106" OR ABSTRACT:"INBRX-106" OR TITLE:"Hexavalent OX40 agonist antibody" OR ABSTRACT:"Hexavalent OX40 agonist antibody") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about INBRX-106, not a curated reading list.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.